Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Harbin Gloria Pharma Acquires Shanxi Powerdone for $380 Million

publication date: Feb 3, 2015
Harbin Gloria Pharma will pay $380 million to acquire an 85% stake in Shanxi Powerdone, which makes chemical drugs and compound preparations. To pay for the transaction, Gloria will raise $960 million in a private placement. In addition, Gloria will allocate another $183 million in capex to several company infrastructure improvements. And, two months ago, Gloria spent $24 million to acquire the remaining 30% stake in Guangzhou Xinhuacheng Biotech, gaining a production base for ginkgolide B injections. More details....

Stock Symbol: (SHE: 002437)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital